New findings presented at ASCO 2026 show that a CAR-T cell therapy called Breyanzi (lisocabtagene maraleucel) is producing ...
Gastrointestinal prophylaxis reduced Grade ≥ 2 diarrhea/colitis from 55% without prophylaxis to 10% with prophylaxisThe ...
High objective response rate of 92.9% in second line patients who have progressed on a BTK inhibitor and have not received BCL2 inhibitor ...
New research co-led by a Roswell Park Comprehensive Cancer Center leukemia expert highlights a promising investigational ...
Sumitomo Pharma America, Inc. (SMPA) today announced that it has enrolled the required number of participants in its pivotal Phase 2 monotherapy trial for enzomenib, an investigational, oral selective ...
ARTEMIS-001: Data from a phase 1a/b study of HS-20093 in patients with relapsed small cell lung cancer (SCLC). DoR (mo), median (95% CI) 7.6 (5.4-9.7) 6.3 (3.9-9.7) 8.4 (4.6-12.7) 8.2 (5.4-11.7) PFS ...
Multiple myeloma is considered to be relapsed if symptoms of the disease appear after a time of improvement. It’s considered to be refractory when it gets worse even though it’s being treated. To ...
Please provide your email address to receive an email when new articles are posted on . The FDA approved revumenib for patients aged 1 year and older with relapsed or refractory acute myeloid leukemia ...
Patients with relapsed multiple myeloma treated with the immunotherapy teclistamab lived significantly longer and remained in remission far longer than those receiving standard therapies, according to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results